A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study

Table 2 Differences between treatment modalities as per the 2005 St. Gallen guidelines

Risk Category	Endocrine responsive	Endocrine response uncertain	Endocrine nonresponsive
Low risk	ET or Nil	ET or Nil	Not applicable
Intermediate risk	ET alone, or	CT → ET	CT
	CT → ET	(CT + ET)
	(CT + ET)
High risk	CT → ET	CT → ET	CT
	(CT + ET)	(CT + ET)

Abbreviations: ET, endocrine therapy; Nil, no adjuvant systemic therapy; CT, chemotherapy.

ISSN: 1471-2407